Pharma-Bio Serv, Inc 8-K, filed Mar 16, 2020
Pharma-Bio Serv, Inc. (PBSV)
8-K
2020-03-16
For: 2020-03-16
View Original
Added on
April 06, 2026
About this 8-K
Pharma-Bio Serv, Inc filed this 8-K on March 16, 2020.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): March 16,
2020
Pharma-Bio Serv, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
6 Road
696, Dorado, Puerto Rico
|
00646
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(787)
278-2709
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b2).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition
On
March 16, 2020, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing
its results of operations for the three months ended January 31,
2020. A copy of the press release is furnished as
Exhibit 99.1 to this
report
The
information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities under that section and shall not be deemed to be
incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
Press
Release, dated March 16, 2020
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
PHARMA-BIO
SERV, INC.
|
|
|
|
|
|
|
|
|
Date:
March 16, 2020
|
By:
|
/s/ Pedro
J. Lasanta
|
|
|
|
|
Pedro
J. Lasanta
|
|
|
|
|
Chief
Financial Officer, Vice President Finance and Administration and
Secretary
|
|
|
|
|
|
|
Exhibit 99.1
Pharma-Bio Serv Announces Results for the Quarter Ended January 31,
2020
March 16, 2020
DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2020 /
Pharma-Bio Serv, Inc. ("Pharma-Bio
Serv" or the "Company") (OTCQB: PBSV), a compliance, project
management and technology transfer support consulting firm that
provides services to the pharmaceutical, biotechnology, chemical,
medical device, cosmetic, food and allied products industries,
today announced revenues from continuing operations for the quarter
ended January 31, 2020 were $4,613,000, a net increase of
approximately $47,000 when compared to the same period last year.
The revenue increase is mainly attributable to the increase in
projects in the Puerto Rico market for approximately $292,000,
while the US, Europe and Brazil markets had an aggregate decrease
in projects revenue for approximately $245,000.
Net income for the three months ended January 31, 2020 was
approximately $527,000, reflecting no significant change when
compared to the same period last year.
“During this challenging time as the coronavirus COVID-19
pandemic continues, we are committed to the health and well-being
of our consultants, customers, customer’s patients and
consumers. As such, we are supporting all government and customer
initiatives to safeguard the health of our people and our
customers. The
healthcare industry has come together to work on the solutions to
today’s challenges in a fast-pace and safe manner. Our
services and expertise are critical to the operations and quality
objectives of our customers; and we believe we have the resources
for our services to continue uninterrupted,” said Victor
Sanchez, CEO of Pharma-Bio Serv, Inc.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv is a compliance, project management, and technology
transfer support consulting firm, headquartered in Puerto Rico,
servicing the Puerto Rico, United States, Europe and Brazil
markets. Pharma-Bio Serv's core business is FDA and international
agencies regulatory compliance consulting related services. The
Company's global team includes leading engineering and life science
professionals, quality assurance managers and
directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the
meaning of the U.S. federal securities laws, which statements may
include information regarding the plans, intentions, expectations,
future financial performance, or future operating performance of
Pharma-Bio Serv. Forward-looking statements are based on the
expectations, estimates, or projections of management as of the
date of this news release. Although Pharma-Bio Serv's management
believes these expectations, estimates, or projections to be
reasonable as of the date of this news release, forward-looking
statements are inherently subject to significant business risks,
economic and competitive uncertainties, or other contingencies,
which could cause its actual results or performance to differ
materially from what may be expressed or implied in the
forward-looking statements. Important factors that could cause
Pharma-Bio Serv's actual results or performance to differ
materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual
Report on Form 10-K for the year ended October 31, 2019, and in its
other filings with the Securities and Exchange Commission, which
filings are available on www.sec.gov.
Pharma-Bio Serv disclaims any intention or obligation to update or
revise any forward-looking statements to reflect subsequent events
and circumstances, except to the extent required by applicable
law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv,
Inc.